Skip to main content
Ulrike Buchwald, MD, Infectious Disease, Lutherville, MD

Ulrike Kirsten Buchwald MD

HIV/AIDS Medicine, International Health, Travel & Tropical, Mycobacterial Disease, STD Medicine


Director, Clinical Vaccine Research, Merck & Co Clinical Assistant Professor, Medicine, University of Maryland School of Medicine

Join to View Full Profile
  • Johns Hopkins Gastroenterology Green Spring Station2360 W Joppa RdLutherville, MD 21093

  • Phone+1 410-933-7495

Dr. Buchwald is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • London School of Hygiene and Tropical Medicine
    London School of Hygiene and Tropical MedicineMS, Public Health, 2014 - 2019
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineFellowship, Infectious Disease, 2007 - 2010
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Internal Medicine, 2004 - 2007
  • Freie University Berlin Faculty of Medicine
    Freie University Berlin Faculty of MedicineClass of 1998

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2010 - 2026
  • PA State Medical License
    PA State Medical License 2016 - 2018
  • NJ State Medical License
    NJ State Medical License 2010 - 2011
  • NY State Medical License
    NY State Medical License 2009 - 2011
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Infectious Disease
    American Board of Internal Medicine Infectious Disease

Publications & Presentations

PubMed

Press Mentions

  • Pancreatic Cancer Clinical Trials: Insights from PanCAn’s Senior Director
    Pancreatic Cancer Clinical Trials: Insights from PanCAn’s Senior DirectorDecember 16th, 2023
  • CMV Vaccine Trials: Moderna’s CMV mRNA Vaccine Enters Phase III
    CMV Vaccine Trials: Moderna’s CMV mRNA Vaccine Enters Phase IIIFebruary 20th, 2024
  • Merck’s Capvaxive Wins FDA Approval as First Pneumonia Vaccine Designed for Adults
    Merck’s Capvaxive Wins FDA Approval as First Pneumonia Vaccine Designed for AdultsJune 22nd, 2024

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: